LivaNova (NASDAQ:LIVN) Given New $55.00 Price Target at The Goldman Sachs Group

LivaNova (NASDAQ:LIVN) had its target price decreased by The Goldman Sachs Group from $64.00 to $55.00 in a research report report published on Monday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

LIVN has been the topic of several other research reports. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Needham & Company LLC reduced their target price on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus reduced their target price on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Mizuho decreased their price objective on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Finally, StockNews.com lowered shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 26th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $62.20.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $41.72 on Monday. The firm’s 50 day moving average is $47.30 and its two-hundred day moving average is $49.52. LivaNova has a 52 week low of $40.37 and a 52 week high of $64.47. The firm has a market capitalization of $2.27 billion, a P/E ratio of 99.33 and a beta of 1.00. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Insider Activity

In other news, Director Francesco Bianchi sold 1,250 shares of the firm’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now owns 7,522 shares in the company, valued at approximately $383,546.78. This trade represents a 14.25 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. raised its holdings in LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares during the period. Sterling Capital Management LLC raised its holdings in LivaNova by 800.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after acquiring an additional 1,441 shares during the period. Central Pacific Bank Trust Division raised its holdings in LivaNova by 21.2% in the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after acquiring an additional 720 shares during the period. Captrust Financial Advisors bought a new position in LivaNova in the 3rd quarter worth $217,000. Finally, Sanctuary Advisors LLC bought a new position in LivaNova in the 3rd quarter worth $219,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.